Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab, Lenvatinib and Gemox in Advanced Intrahepatic Cholangiocarcinoma
NCT03951597Phase 2Unknown
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- May 2019
- Primary completion
- Jan 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in intrahepatic cholangiocarcinoma (ICC), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Objective Response Rate at 12 months. Status: unknown.
02
Drugs
toripalimab
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT03951597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03951597.